For Immediate Release
Chicago, IL – July 6, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk A/S
NVO
, Intel Corp.
INTC
, Qualcomm Inc.
QCOM
, T-Mobile US, Inc.
TMUS
and Sony Group Corp.
SONY
.
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Novo Nordisk, Intel and Qualcomm
The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S, Intel Corp., and Qualcomm Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can
see all of today’s research reports here >>>
Novo Nordisk
shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+32.6% vs. +20.1%) on the back of the company’s promising diabetes drug, Ozempic. The Zacks analyst has described the Rybelsus launch as further strengthening Novo Nordisk’s best-in-class diabetes portfolio.
Ozempic, Rybelsus, Xultophy and Saxenda have been helping the company maintain momentum. Label expansion of these existing drugs is expected to boost sales.
However, lower realized prices in the U.S., loss of exclusivity for products and stiff competition are affecting sales totals. Patent expiration on some of the products in Novo Nordisk’s portfolio is a concern. Sales continue to be negatively impacted by the Covid pandemic. Supply challenges for Wegovy have also hurt the stock.
(You can
read the full research report on Novo Nordisk here >>>
)
Intel
shares have declined -28.3% year to date versus the Zacks Semiconductor – General industry’s decline of -41.6%. The chip-making major reaffirmed its earlier guidance for 2022 despite short-term headwinds, as it expects demand to pick up in the second half of the year.
The company is riding on prospects of the Internet of Things and Mobileye businesses. Mobileye growth should be driven by design wins amid a recovering auto industry. Recovery in the enterprise business of the data center segment is positive. Intel is developing more integrated solutions that will likely be competitive on a cost-per-watt basis while offering customized solutions for bigger firms.
(You can
read the full research report on Intel here >>
>)
Qualcomm
shares have declined -10.9% over the past year against the Zacks Wireless Equipment industry’s decline of -16.7%. The company faces intense competition from low-cost chip manufacturers. High research and development costs are expected to dent margins, while the global chip shortage due to supply-chain disruptions is a headwind. It is susceptible to risks arising from lower handset shipments, especially in China.
However, Qualcomm is focused on retaining its leadership in 5G and the chipset market, delivering low-power resilient multi-gigabit connectivity with best-in-class security. It is witnessing healthy traction in EDGE networking solutions across diverse sectors.
The buyout of Arriver will bolster its ability to deliver fully integrated Advanced Driver Assistance System solutions to automakers. The company is well-positioned to benefit from solid 5G traction with greater visibility and diversified businesses to meet its long-term revenue targets.
(You can
read the full research report on Qcom here >>>
)
Other noteworthy reports we are featuring today include T-Mobile US, Inc. and Sony Group Corp.
Why Haven’t You Looked at Zacks’ Top Stocks?
Our 5 best-performing strategies have blown away the S&P’s impressive +28.8% gain in 2021. Amazingly, they soared
+40.3%, +48.2%, +67.6%, +94.4%,
and
+95.3%
. Today you can access their live picks without cost or obligation.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performance
for information about the performance numbers displayed in this press release.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
